FDA Cannabis News

Tue / Apr 30th

The DEA has reportedly agreed to reschedule cannabis under Schedule III of the Controlled Substances Act, in accordance with the FDA’s recent recommendation. While this development could loosen financial restrictions for brands operating in state markets, advocates have pointed out that it does not resolve the ongoing social injustices surrounding cannabis criminalization, and that it could benefit larger corporate entities that are angling to dominate the market.


Featured Business Profiles

Create a profile View all categories

New to Cannabis? Start Here.

The Ganjapreneur beginner's guide to all things cannabis.